
Please try another search
By Investing.com Staff
Takeover talks between Merck (NYSE:MRK) and Seagen (NASDAQ:SGEN) have accelerated and the two sides are scheduled to meet this week, the Wall Street Journal reported citing people familiar with the matter.
Last week, the Journal originally reported that Merck was in talks to acquire Seagen and others suitors may also be looking.
While the report added that it is unclear if Merck submitted a formal offer, Wall Street analysts have pegged a price of $200+ per share needed to get a deal done.
The two companies already have existing collaborations and Oppenheimer analyst Jay Olson recently noted that Merck and other large biopharma face patent cliffs that could be filled with a deal for Seagen. Olson pointed to Seagen's expertise in ADCs, which have increasing roles in the future oncology treatment paradigm. This, he said, was exemplified by the overwhelming efficacy of Seagen's Enhertu at ASCO2022.
Shares of Seagen gained 4% in pre-open trading Friday to $180 per share.
By Oliver Gray Investing.com - U.S. stock futures were trading slightly lower during Sunday’s evening deals, after major benchmark averages rallied for the 4th consecutive...
(Reuters) - Saudi Arabia's Kingdom Holding invested in Russian energy groups Gazprom (MCX:GAZP), Rosneft and Lukoil between Feb. 22 and March 22, it said on Twitter (NYSE:TWTR) on...
By Rebecca Rubin LOS ANGELES (Variety.com) - Is everyone on vacation? That would be one plausible explanation behind the great box office slowdown. Although three new movies...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.